Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.
Sujatha Nallapareddy, MD, discusses how personalized therapy has improved the outlook for patients with colorectal cancer and sheds light on some of the challenges that lie ahead.
Having a late-stage treatment for pancreatic cancer that avoids many of the adverse events associated with chemotherapy would be a boon for patients.
Christopher Lieu, MD, highlights updates on biomarker-directed therapy with colorectal cancer and ongoing research being done with immunotherapy.
Rutika Mehta, MD, MPH, provides insight on the ongoing study combining TAS-102 with ramucirumab in the treatment of patients with advanced gastric/GEJ cancer.
Wells A. Messersmith, MD, discusses the evolving standards of care in colorectal cancer and the importance of molecular testing in guiding treatment decisions.
S. Lindsey Davis, MD, highlights the latest immunotherapy developments and other advances in gastric and gastroesophageal junction cancers.
Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.
Maintenance therapy with olaparib significantly improved progression-free survival compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.
Frontline pembrolizumab demonstrated non-inferior overall survival compared with standard chemotherapy among patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.